ReviewClinical pharmacokinetics2007
Cholestasis and endogenous opioids: liver disease and exogenous opioid pharmacokinetics.
Review in Clinical pharmacokinetics, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 53 citations in OpenAlex.
- Modulation of social and depression behaviors in cholestatic and drug-dependent mice: possible role of opioid receptors.Journal of diabetes and metabolic disorders · 2023Article
- Endogenous Opioid Levels Do Not Correlate With Itch Intensity and Therapeutic Interventions in Hepatic Pruritus.Frontiers in medicine · 2021Article
- The Correlation Between Heart Failure and Gut Microbiome Metabolites.Infectious microbes & diseases · 2020Review
- Review
- Pituitary protein 7B2 plasma levels in patients with liver disease: Comparisons with other hormones and neuropeptides.Oncology letters · 2013Article
- Article
- Implications of opioid analgesia for medically complicated patients.Drugs & aging · 2010Review
- Bile Duct Dilatation in Patients With Chronic Viral Hepatitis on Maintenance Methadone Therapy.Gastroenterology & hepatology · 2009Article
- Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction.European journal of clinical pharmacology · 2008Review
- Morphine versus fentanyl patient-controlled analgesia for postoperative pain control in major hepatic resection surgeries including living liver donors: A retrospective study.Saudi journal of anaesthesiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A class of endogenous opioids is upregulated in liver disease particular to cholestasis, which contributes to symptoms in liver disease such as pruritus, hypotension and encephalopathy. Symptoms associated with cholestasis are reversed or at least ameliorated by mu opioid receptor antagonists. Palliation of symptoms related to cholestatic liver disease also involves bile acid binding agents. Opioid receptor antagonists, unlike bile acid binding agents, have been reported to relieve multiple symptoms, except for pruritus, and improve liver function as demonstrated in experimental cholestasis. Exogenous opioid pharmacology is altered by liver disease. Dose reduction or prolongation of dose intervals is necessary depending on the severity of liver disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.